Page 29 - GTM-3-1

Global Translational Medicine Role of HTS in cancer therapeutics

doi: 10.1038/s41598‑017‑05458‑y doi: 10.2174/1875397301004010034
157. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of 168. Huang F, Motlekar NA, Burgwin CM, Napper AD,
isogenic human cancer cells for high-throughput screening Diamond SL, Mazin AV. Identification of specific inhibitors
and drug discovery. Nat Biotechnol. 2001;19(10):940‑945. of human RAD51 recombinase using high-throughput
screening. ACS Chem Biol. 2011;6(6):628‑635.
doi: 10.1038/nbt1001‑940
doi: 10.1021/cb100428c
158. Mallon R, Feldberg L, Kim S, et al. Identification of
4-anilino-3-quinolinecarbonitrile inhibitors of mitogen- 169. Huang L, Yi X, Yu X, et al. High‑throughput strategies for the
activated protein/extracellular signal-regulated kinase 1 discovery of anticancer drugs by targeting transcriptional
kinase. Mol Cancer Ther. 2004;3(6):755‑762. reprogramming. Front Oncol. 2021;11:762023.
159. Rissmann R, Hessel MH, Cohen AF. Vemurafenib/ doi: 10.3389/fonc.2021.762023
dabrafenib and trametinib. Br J Clin Pharmacol. 170. Shaw J, Dale I, Hemsley P, et al. Positioning high-throughput
2015;80(4):765‑767.
CETSA in early drug discovery through screening against
doi: 10.1111/bcp.12651 B‑Raf and PARP1. SLAS Discov. 2019;24(2):121‑132.
160. Fu H, Gao H, Qi X, et al. Aldolase A promotes proliferation doi: 10.1177/2472555218813332
and G 1/S transition via the EGFR/MAPK pathway in 171. Howard RT, Hemsley P, Petteruti P, et al. Structure-guided
non‑small cell lung cancer. Cancer Commun (Lond). design and in-cell target profiling of a cell-active target
2018;38:18.
engagement probe for PARP inhibitors. ACS Chem Biol.
doi: 10.1186/s40880‑018‑0290‑3 2020;15(2):325‑333.
161. Champer M, Miller D, Kuo DYS. Response to trametinib doi: 10.1021/acschembio.9b00963
in recurrent low-grade serous ovarian cancer with NRAS 172. Cancer Genome Atlas Research Network. Comprehensive
mutation: A case report. Gynecol Oncol Rep. 2019;28:26‑28.
genomic characterization defines human glioblastoma genes
doi: 10.1016/j.gore.2019.01.007 and core pathways. Nature. 2008;455(7216):1061‑1068.
162. Liu S, Zou Q, Chen JP, et al. Targeting enhancer doi: 10.1038/nature07385
reprogramming to mitigate MEK inhibitor resistance
in preclinical models of advanced ovarian cancer. J Clin 173. Ding L, Getz G, Wheeler DA, et al. Somatic mutations
Invest. 2021;131(20):e145035. affect key pathways in lung adenocarcinoma. Nature.
2008;455(7216):1069‑1075.
doi: 10.1172/jci145035
doi: 10.1038/nature07423
163. Yuliantie E, Dai X, Yang D, Crack PJ, Wang MW. High‑ 174. Jones S, Zhang X, Parsons DW, et al. Core signaling
throughput screening for small molecule inhibitors of the pathways in human pancreatic cancers revealed by global
type‑I interferon signaling pathway. Acta Pharm Sin B. genomic analyses. Science. 2008;321(5897):1801‑1806.
2018;8(6):889‑899.
doi: 10.1126/science.1164368
doi: 10.1016/j.apsb.2018.07.005
175. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer
164. Dillon KJ, Smith GC, Martin NM. A FlashPlate assay for
the identification of PARP‑1 inhibitors. J Biomol Screen. Res Treat. 1998;52(1‑3):17‑28.
2003;8(3):347‑352. doi: 10.1023/a:1006102916060
doi: 10.1177/1087057103008003013 176. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of
centrosomal kinase STK15/BTAK mRNA expression with
165. Bapat A, Glass LS, Luo M, et al. Novel small‑molecule chromosomal instability in human breast cancers. Int J
inhibitor of apurinic/apyrimidinic endonuclease 1 blocks
proliferation and reduces viability of glioblastoma cells. Cancer. 2001;92(3):370‑373.
J Pharmacol Exp Ther. 2010;334(3):988‑998. doi: 10.1002/ijc.1200
doi: 10.1124/jpet.110.169128 177. Dhillon NK, Mudryj M. Cyclin E overexpression enhances
cytokine‑mediated apoptosis in MCF7 breast cancer cells.
166. Peterson EJ, Janzen WP, Kireev D, Singleton SF. High-
throughput screening for RecA inhibitors using a Genes Immun. 2003;4(5):336‑342.
transcreener adenosine 5’-O-diphosphate assay. Assay doi: 10.1038/sj.gene.6363973
Drug Dev Technol. 2012;10(3):260‑268.
178. Niu D, Wang G, Wang X. Up‑regulation of cyclin E in
doi: 10.1089/adt.2011.0409 breast cancer via estrogen receptor pathway. Int J Clin Exp
Med. 2015;8(1):910‑915.
167. Sexton JZ, Wigle TJ, He Q, et al. Novel inhibitors of E. coli
RecA ATPase activity. Curr Chem Genomics. 2010;4:34‑42. 179. Warner SL, Munoz RM, Stafford P, et al. Comparing

Volume 3 Issue 1 (2024) 21 https://doi.org/10.36922/gtm.2448